NYXH
NyxoahKey Statistics
About Nyxoah
Nyxoah is a leading medical technology company focused on revolutionizing the treatment of obstructive sleep apnea (OSA) through its groundbreaking Genio system, which utilizes minimally invasive hypoglossal nerve stimulation techniques. With a strong commitment to clinical validation and ongoing research, Nyxoah aims to significantly improve patient outcomes and overall quality of life for individuals suffering from OSA. The company's strategic focus on innovation and technology, enhanced by robust partnerships and comprehensive studies, positions it well to capitalize on unmet needs within the sleep medicine market, highlighting its potential for sustainable growth and impactful contributions to the healthcare landscape.
Fundamentals
| Revenue (TTM) | $10.02M |
| Gross Profit (TTM) | $6.33M |
| EBITDA | $-82.35M |
| Operating Margin | -329.30% |
| Return on Equity | -110.90% |
| Return on Assets | -37.70% |
| Revenue/Share (TTM) | $0.26 |
| Book Value | $1.34 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 12.77 |
| EV/Revenue | 10.14 |
| EV/EBITDA | -2.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 346.90% |
| Shares Outstanding | $43.66M |
| Float | $24.49M |
| % Insiders | 37.03% |
| % Institutions | 21.52% |
Historical Volatility
Volatility is currently contracting